Complete financial analysis of Apollo Endosurgery, Inc. (APEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollo Endosurgery, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Australian Agricultural Company Limited (AAC.AX) Income Statement Analysis – Financial Results
- Sparinvest SICAV – European Value (SSIEUVEURR.CO) Income Statement Analysis – Financial Results
- Blackbird plc (BIRD.L) Income Statement Analysis – Financial Results
- Hang Tai Yue Group Holdings Limited (8081.HK) Income Statement Analysis – Financial Results
- Delaware Investments Dividend and Income Fund, Inc. (DDF) Income Statement Analysis – Financial Results
Apollo Endosurgery, Inc. (APEN)
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.86M | 62.99M | 42.05M | 50.71M | 60.85M | 64.31M | 64.87M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Cost of Revenue | 34.43M | 28.03M | 19.81M | 25.04M | 27.66M | 24.58M | 25.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 42.43M | 34.96M | 22.24M | 25.68M | 33.19M | 39.73M | 39.61M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Gross Profit Ratio | 55.20% | 55.50% | 52.90% | 50.63% | 54.55% | 61.78% | 61.07% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 11.91M | 9.52M | 7.67M | 10.38M | 12.18M | 8.30M | 7.81M | 8.51M | 18.13M | 11.34M | 8.16M | 9.73M | 7.82M | 6.63M | 10.12M | 12.42M | 4.04M | 1.48M |
| General & Administrative | 20.58M | 18.45M | 11.06M | 13.59M | 13.44M | 13.72M | 13.63M | 3.95M | 4.76M | 4.23M | 4.09M | 0.00 | 4.50M | 3.48M | 4.48M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.01M | 24.31M | 17.36M | 28.73M | 32.83M | 32.91M | 31.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.59M | 42.76M | 28.42M | 42.32M | 46.27M | 46.63M | 45.38M | 3.95M | 4.76M | 4.23M | 4.09M | 3.37M | 4.50M | 3.48M | 4.48M | 3.43M | 2.23M | 1.66M |
| Other Expenses | 1.75M | 1.88M | 1.95M | 2.10M | 7.07M | 7.24M | 7.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 70.25M | 54.16M | 38.04M | 54.80M | 65.52M | 62.17M | 60.37M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Cost & Expenses | 104.68M | 82.19M | 57.84M | 79.84M | 93.18M | 86.75M | 85.63M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.04K | 398.02K | 161.24K | 7.95K |
| Interest Expense | 4.67M | 8.32M | 5.25M | 4.05M | 4.06M | 4.51M | 18.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.12K | 27.95K | 0.00 | 157.13K |
| Depreciation & Amortization | -196.00K | 2.01M | 2.31M | 2.50M | 9.29M | 9.72M | 9.09M | 466.99K | 216.09K | 196.22K | 187.50K | 141.99K | 165.30K | 176.69K | 215.02K | 156.44K | 49.57K | 81.18K |
| EBITDA | -31.42M | -17.19M | -13.49M | -26.62M | -40.09M | -12.76M | -20.76M | -9.54M | -17.81M | -7.59M | -5.56M | -2.97M | 0.00 | 0.00 | -11.23M | -15.48M | -5.56M | -2.40M |
| EBITDA Ratio | -36.46% | -27.28% | -32.08% | -52.49% | -52.98% | -19.85% | -20.84% | -596.55% | -321.60% | -79.74% | -38.35% | -31.66% | -56.62% | 34.93% | -392.60% | -4,003.61% | -1,085.29% | -344.22% |
| Operating Income | -27.82M | -19.20M | -15.79M | -29.12M | -40.09M | -22.44M | -20.76M | -10.86M | -17.81M | -7.59M | -5.56M | -3.71M | -4.49M | 1.80M | -11.74M | -15.48M | -5.77M | -2.40M |
| Operating Income Ratio | -36.20% | -30.48% | -37.56% | -57.43% | -65.88% | -34.89% | -32.00% | -678.87% | -350.46% | -95.05% | -83.16% | -39.52% | -57.29% | 15.13% | -410.16% | -4,156.30% | -1,126.47% | -323.39% |
| Total Other Income/Expenses | -7.83M | -5.33M | -6.68M | 1.97M | -5.50M | -4.55M | -20.02M | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 163.33K | 384.12K | 0.00 | -402.84K |
| Income Before Tax | -39.26M | -24.53M | -22.47M | -27.16M | -45.60M | -26.99M | -40.78M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.57M | -15.46M | 0.00 | -2.65M |
| Income Before Tax Ratio | -51.08% | -38.94% | -53.44% | -53.55% | -74.93% | -41.97% | -62.87% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -404.45% | -4,152.52% | 0.00% | -356.21% |
| Income Tax Expense | 584.00K | 156.00K | 142.00K | 275.00K | 191.00K | 304.00K | 387.00K | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 175.45K | 42.00K | 0.00 | -86.79K |
| Net Income | -39.84M | -24.68M | -22.61M | -27.43M | -45.79M | -27.29M | -41.17M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.46M | -15.09M | -5.60M | -2.80M |
| Net Income Ratio | -51.84% | -39.18% | -53.77% | -54.09% | -75.24% | -42.44% | -63.46% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -400.54% | -4,053.13% | -1,094.97% | -376.28% |
| EPS | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 39.63 | -128.50 | -209.81 | -123.52 | -365.69 |
| EPS Diluted | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 37.78 | -128.50 | -209.81 | -123.52 | -365.69 |
| Weighted Avg Shares Out | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 100.52K | 89.18K | 71.93K | 45.38K | 7.65K |
| Weighted Avg Shares Out (Dil) | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 105.43K | 89.18K | 71.93K | 45.38K | 7.65K |
Apollo Endosurgery to Report Second Quarter 2017 Financial Results on August 1, 2017
Apollo Endosurgery to Report First Quarter 2017 Financial Results on May 4, 2017
Apollo Endosurgery to Report Fourth Quarter and Full Year 2016 Financial Results on March 8, 2017
Source: https://incomestatements.info
Category: Stock Reports